U4atac_minor_spliceosomal_RNA

U4atac minor spliceosomal RNA

U4atac minor spliceosomal RNA

Add article description


U4atac minor spliceosomal RNA is a ncRNA which is an essential component of the minor U12-type spliceosome complex. The U12-type spliceosome is required for removal of the rarer class of eukaryotic introns (AT-AC, U12-type).[1]

Quick Facts Identifiers, Symbol ...

U4atac snRNA is proposed to form a base-paired complex with another spliceosomal RNA U6atac via two stem loop regions. These interacting stem loops have been shown to be required for in vivo splicing.[2] U4atac also contains a 3' Sm protein binding site which has been shown to be essential for splicing activity.[2] U4atac is the functional analog of U4 spliceosomal RNA in the major U2-type spliceosomal complex.[2]

The Drosophila U4atac snRNA has an additional predicted 3' stem loop terminal to the Sm binding site.[3]

Disease

It has been shown that mutations in the U4atac snRNA can cause microcephalic osteodysplastic primordial dwarfism type I (MOPD I), also called Taybi-Linder syndrome (TALS). MOPD I is a developmental disorder that is associated with brain and skeletal abnormalities. It has been shown that the mutations cause defective U12 splicing.[4][5]


References

  1. Lorkovic ZJ, Lehner R, Forstner C, Barta A (2005). "Evolutionary conservation of minor U12-type spliceosome between plants and humans". RNA. 11 (7): 1095–1107. doi:10.1261/rna.2440305. PMC 1370794. PMID 15987817.
  2. Shukla GC, Cole AJ, Dietrich RC, Padgett RA (2002). "Domains of human U4atac snRNA required for U12-dependent splicing in vivo". Nucleic Acids Res. 30 (21): 4650–4657. doi:10.1093/nar/gkf609. PMC 135832. PMID 12409455.
  3. Edery, P; et al. (2011). "Association of TALS developmental disorder with defect in minor splicing component U4atac snRNA". Science. 332 (6026): 240–243. doi:10.1126/science.1202205. PMID 21474761. S2CID 11354957.



Share this article:

This article uses material from the Wikipedia article U4atac_minor_spliceosomal_RNA, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.